Consulting-Specifying Engineer - September 2007 - (Page 69)

mutate or evolve into new variants (Pimentel et al, 1998). The multifaceted problem of drug resistance in nosocomial pathogens threatens to extend explosively beyond the boundaries of health care settings and we are witnessing their occurrences in communities, prisons, athletic facilities, agricultural environments and even battlefields. It may be time to consider more drastic solutions than drug treatment alone, and options may include disease management methods such as quarantine and health education, and engineering methods such as air treatment. The latter approach has great unexplored potential. Although it may not be a complete solution, it may, if implemented on a wide enough basis, be capable of limiting epidemics and providing healthy, safe environments in which to live and work. References Ampel, M.N. “Emerging Disease Issues and Fungal Pathogens Associated with HIV Infection.” Emerging Infectious Diseases 2.2 (1996). Andersson E., P. Horal, A. Vahlne and B. Svennerholm. “No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycylprolyl-glycine-amide.” Antiviral Research 61.2 (2004):119-124. Andrei G., E. DeClercq and R. Snoeck “In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?” Antiviral Research 61.3 (2004):181-187. “Antimicrobial Resistance.” World Health Organization Fact Sheet No. 194. 2002. Baddour L.M., W.R. Wilson, A.S. Bayer et al. “AHA Scientific Statement: Infective Endocarditis.” Circulation 111 (2005): 3167-3184. “Benching Bacteria from Athletics: New Sporting Goods Line Answers Call for Protection Against Antibiotic-Resistant Staph Infections.” PRNewswire. (2005). Bright R.A., D. Shay, J. Bresee, A. Klimov and N. Cox. “High Levels of Adamantane Resistance Among Influenza A (H3N2) Viruses and Interim Guidelines for Use of Antiviral Agents—United States, 2005-06 Influenza Season.” MMWR 55.02 (2006):44-46. Davis K.A., K.A. Moran, C.K. McAllister and P.J. Gray. “Multi-Drug Resistant Acinetobacter Extremity Infections in Soldiers.” Emerging Infectious Diseases 11.8 (2005): 1218-1224. Ewald, P. The Evolution of Infectious Disease. Oxford University Press. 1994. Falagas, M.E. and S.K. Kasiakou. “Correct use of the term ‘pan-drug-resistant’ (PDR) Gram-negative bacteria.” Clinical Microbiology and Infectection 11.12 (2005): 1049-1050 Huang H.V. “Antiviral Drugs and RNA Viruses.” Washington University School of Medicine 2005. http://www.microbiology. wustl.edu/dept/fac/huang/ccas/intro.html Jain D.L. and V. Agarwal. “Multi-drug resistant invasive isolates of haemophilus influenzae: a multi-center study in India: indiaclen ibis study group.” Journal of Clinical Epidemology 50.01 (1996): 16S. Kowalski W.J. Aerobiological Engineering Handbook: A Guide to Airborne Disease Control Technologies. New York: McGrawHill. 2006. Moellering, R.C. “The Growing Menace of Community-Acquired Methicillin-Resistant Staphylococcus aureus.” Annals of Internal Medicine 144.5 (2006): 368-370. Perumal S.R., A. Pachiappan, P. Gopalakrishnakone, M. Thwin, Y. Hian, V. Chow, H. Bow and J. Weng. “In vitro antimicrobial activity of natural toxins and animal venoms tested against Burkholderia pseudomallei.” BMC Infectious Diseases 6.1 (2006): 100. Pimentel D, M. Tort, L. D’Anna, A. Krawic, J. Berger, J. Rossman, F. Mugo, N. Doon, M. Shriberg, E. Howard and others. “Ecology of Increasing Disease: Population growth and environmental degradation.” Bioscience 48.10 (1998). Platt A.E. “Infecting ourselves: How environmental and social disruptions trigger disease.” Washington: Worldwatch Institute 129 (1996). “Report of the ASM task force on antibiotic resistance.” American Society for Microbiology (1994). Ryan K.J. Sherris Medical Microbiology Norwalk: Appleton & Lange. 1994. “Tuberculosis control in the WHO European Region.” World Health Organization Europe Fact Sheet 07/02. 2002. VandenBossche H., F. Dromer, L. Improvisi, M. Lozano-Chiu, J.H. Rex and D. Sanglard. “Antifungal drug resistance in pathogenic fungi.” Medical Mycology 36.01 (1998): 119-128. Weinstein, R.A. 2004. “Planning for Epidemic —The Lessons of SARS.” NEJM 350(23) (2004): 2332-2334. Water works Reliable standby power systems from Cummins Power Generation Inc. meet your requirements for pumping stations, wastewater treatment plants and other municipal installations. > High-performance for motor-starting loads > Permanently-installed or trailerized > 24/7 support from your local distributor For our free white paper, “How to size a genset,” visit www.cumminspower. com/municipal © 2007 Cummins Power Generation Inc. Input #240 at csemag.com/quickResponse http://www.microbiology.wustl.edu/dept/fac/huang/ccas/intro.html http://www.microbiology.wustl.edu/dept/fac/huang/ccas/intro.html http://www.cumminspower.com/municipal http://www.cumminspower.com/municipal http://www.cumminspower.com/municiple http://csemag.com/quickResponse

Table of Contents Feed for the Digital Edition of Consulting-Specifying Engineer - September 2007

Contents M/E Roundtable Cover Story: Airborne Superbugs Third-Party Liability Back to School Product Spotlight Codes & Standards Professional Practices How To New Products Jobs/Cliassifieds Specifier’s Notebook Pure Power Supplement New Technologies, Same Old Transmission Problems Wireless Battery Recharging Solar Concentration Renewables Tracking System A Mighty Wind The Importance of Load Bank Testing Quality Power for Security Systems

Consulting-Specifying Engineer - September 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.